Athira Pharma (NASDAQ:ATHA) Issues Earnings Results

Athira Pharma (NASDAQ:ATHA) posted its quarterly earnings data on Thursday. The company reported ($0.70) earnings per share for the quarter, beating the consensus estimate of ($0.75) by $0.05, Zacks reports.

Athira Pharma Price Performance

Shares of ATHA stock traded down $0.04 on Friday, reaching $3.21. 43,156 shares of the stock were exchanged, compared to its average volume of 140,503. The stock has a 50 day moving average price of $2.82 and a 200 day moving average price of $2.81. The stock has a market cap of $123.04 million, a PE ratio of -1.05 and a beta of 2.90. Athira Pharma has a one year low of $1.33 and a one year high of $4.30.

Analyst Upgrades and Downgrades

Separately, JMP Securities reissued a “market outperform” rating and issued a $19.00 price target on shares of Athira Pharma in a report on Thursday, June 20th.

Insider Activity at Athira Pharma

In other Athira Pharma news, Director Kelly A. Romano purchased 27,400 shares of the company’s stock in a transaction that occurred on Monday, June 24th. The stock was acquired at an average cost of $2.42 per share, with a total value of $66,308.00. Following the completion of the purchase, the director now directly owns 80,715 shares in the company, valued at approximately $195,330.30. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. In related news, Director Kelly A. Romano purchased 15,000 shares of the stock in a transaction dated Friday, June 21st. The stock was bought at an average cost of $2.26 per share, with a total value of $33,900.00. Following the purchase, the director now directly owns 53,315 shares in the company, valued at approximately $120,491.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Kelly A. Romano bought 27,400 shares of the business’s stock in a transaction on Monday, June 24th. The stock was purchased at an average price of $2.42 per share, for a total transaction of $66,308.00. Following the completion of the acquisition, the director now owns 80,715 shares of the company’s stock, valued at approximately $195,330.30. The disclosure for this purchase can be found here. 19.80% of the stock is owned by company insiders.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.